Two Grams BID Is an Oral Dosage of Vitamin C to Reduce the Risk of Recurrence of Superficial Bladder Carcinoma

DOI: 10.4236/jct.2015.62019   PDF   HTML   XML   2,932 Downloads   3,733 Views   Citations

Abstract

Background: Continuous exposure to millimolar (mM) Vitamin C (AA) in vitro kills cancer cells. For superficial bladder carcinoma (SBC), standard chemotherapy is instillation of Bacillus Calmette-Guerin. The recurrence rate with this therapy is 91%. But high dosage vitamins including AA reduced the recurrence to 41%. Aim: To determine the oral dosage of AA that causes the highest concentration of AA [AA] in the bladder. Method: We conducted a clinical trial of 14 people who took various dosages of AA, and analyzed the [AA] in their urine. Results: AA above 2 g twice a day was not absorbed. But that intake produced a bladder [AA] above 1 mM in all participants. Conclusion: Taking 2 g of AA BID will increase [AA] in the bladder to a level likely to kill cancer cells that cause SBC. Taking that dosage 2 consecutive days a week is likely to reduce the recurrence rate of SBC substantially.

Share and Cite:

Folk, E. , Downs, T. and Ordman, A. (2015) Two Grams BID Is an Oral Dosage of Vitamin C to Reduce the Risk of Recurrence of Superficial Bladder Carcinoma. Journal of Cancer Therapy, 6, 169-176. doi: 10.4236/jct.2015.62019.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] Cameron, E. and Pauling, L. (1978) Supplemental Ascorbate in the Supportive Treatment of Cancer: Reevaluation of Prolongation of Survival Times in Terminal Human Cancer. Proceedings of the National Academy of Sciences of the United States of America, 75, 4538-4542.
http://dx.doi.org/10.1073/pnas.75.9.4538
[2] Chen, Q., Levine, M., Buettner, G.R., et al. (2005) Pharmacologic Ascorbic Acid Concentrations Selectively Kill Cancer Cells: Action as a Pro-Drug to Deliver Hydrogen Peroxide to Tissues. Proceedings of the National Academy of Sciences of the United States of America, 102, 13604-13609.
http://dx.doi.org/10.1073/pnas.0506390102
[3] Cameron, E. and Campbell, A. (1974) The Orthomolecular Treatment of Cancer. II. Clinical Trial of High-Dose Ascorbic Acid Supplements in Advanced Human Cancer. Chemico-Biological Interactions, 9, 285-315. http://dx.doi.org/10.1016/0009-2797(74)90019-2
[4] Cameron, E. and Pauling, L. (1976) Supplemental Ascorbate in the Supportive Treatment of Cancer: Prolongation of Survival Times in Terminal Human Cancer. Proceedings of the National Academy of Sciences of the United States of America, 73, 3685-3689. http://dx.doi.org/10.1073/pnas.73.10.3685
[5] Olney, K.E., et al. (2013) Inhibitors of Hydroperoxide Metabolism Enhance Ascorbate-Induced Cytotoxicity. Free Radical Research, 47, 154-163. http://dx.doi.org/10.3109/10715762.2012.755263
[6] Creagan, E.T., et al. (1979) Failure of High-Dose Vitamin C (Ascorbic Acid) Therapy to Benefit Patients with Advanced Cancer: A Controlled Trial. The New England Journal of Medicine, 301, 687-690.
http://dx.doi.org/10.1056/NEJM197909273011303
[7] Moertel, C.G., et al. (1985) High-Dose Vitamin C versus Placebo in the Treatment of Patients with Advanced Cancer That Have Had No Prior Chemotherapy. The New England Journal of Medicine, 312, 137-141. http://dx.doi.org/10.1056/NEJM198501173120301
[8] Padayatty, S.J., et al. (2004) Vitamin C: Intravenous Use by Complementary and Alternative Medicine Practitioners and Adverse Effects. Annals of Internal Medicine, 140, 533-537.
http://dx.doi.org/10.7326/0003-4819-140-7-200404060-00010
[9] Levine, M., et al. (1996) Vitamin C Pharmacokinetics in Healthy Volunteers: Evidence for a Recommended Dietary Allowance. Proceedings of the National Academy of Sciences of the United States of America, 93, 3704-3709. http://dx.doi.org/10.1073/pnas.93.8.3704
[10] Buetter, G.R., et al. (2011) Comment on “Pharmacologic Ascorbate Synergizes with Gemcitabine in Pre-Clinical Models of Pancreatic Cancer” i.e. All We Are Saying Is, Give C a Chance. Free Radical Biology and Medicine, 50, 1726-1727. http://dx.doi.org/10.1016/j.freeradbiomed.2011.03.030
[11] Clinical Trials (2013) www.clinicaltrials.gov
[12] National Cancer Institute (2012) Cancer Statistics. http://seer.cancer.gov/statfacts/html/urinb.html
[13] Morales, A. (1980) Treatment of Carcinoma in Situ of the Bladder with BCG. Cancer Immunology, Immunotherapy, 9, 69-72. http://dx.doi.org/10.1007/BF00199531
[14] Lamm, D.L., Riggs, D.R., Shriver, J.S., van Gilder, P.F., Rach, J.F. and De Haven, J.I. (1994) Megadose Vitamins in Bladder Cancer: A Double-Blind Clinical Trial. Journal of Urology, 151, 21-26.
[15] King, G., Beins, M., Larkin, J., Summers, B. and Ordman, A.B. (1994) Rate of Excretion of Vitamin C in Human Urine. AGE, 17, 87-92. http://dx.doi.org/10.1007/BF02435011
[16] Cone, A., Danner, T. and Ordman, A.B. (1996) Urinary Excretion of Calcium in Students and Mature Women Taking Supplements. AGE, 19, 164.
[17] Schleicher, R.L., Carroll, M.D., Ford, E.S. and Lacher, D.A. (2009) Serum Vitamin C and the Prevalence of Vitamin C Deficiency in the United States: 2003-2004 National Health and Nutrition Examination Survey (NHANES). American Journal of Clinical Nutrition, 90, 1252-1263.
http://dx.doi.org/10.3945/ajcn.2008.27016
[18] Moynihan, T. (2012) High-Dose Vitamin C: Can It Kill Cancer Cells? Mayo Clinic Health Information. http://www.mayoclinic.com/health/alternative-cancer-treatment/AN01572
[19] Levine, M., Padayatty, S.J. and Espey, M.G. (2011) Vitamin C: A Concentration-Function Approach Yields Pharmacology and Therapeutic Discoveries. Advances in Nutrition, 2, 78-88.
http://dx.doi.org/10.3945/an.110.000109
[20] Evers, E. (2012) Treat Cancer with IV Vitamin C—Recent Clinical Success. Natural News.
http://www.naturalnews.com/034663_IV_vitamin_c_cancer_treatment.html
[21] Omaye, S.T., Turnbull, J.D. and Sauberlich, H.E. (1979) Selected Methods for the Determination of Ascorbic Acid in Animal Cells. Methods in Enzymology, 62, 3-11.
http://dx.doi.org/10.1016/0076-6879(79)62181-X
[22] Institute of Medicine (2000) Panel on Dietary Antioxidants and Related Compounds, Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids. National Academies Press, Washington DC.
[23] Maserejian, N.N., Giovannucci, E.L., McVary, K.T. and McKinlay, J.B. (2011) Dietary, but Not Supplemental, Intakes of Carotenoids and Vitamin C Are Associated with Decreased Odds of Lower Urinary Tract Symptoms in Men. Journal of Nutrition, 141, 267-273. http://dx.doi.org/10.3945/jn.110.132514
[24] Naidu, K.A. (2003) Vitamin C in Human Health and Disease Is Still a Mystery? An Overview. Journal of Nutrition, 2, 7-23. http://dx.doi.org/10.1186/1475-2891-2-7
[25] Thomas, L.D.K., Elinder, C.-G., Tiselius, H.-G., Wolk, A. and Akesson, A. (2013) Ascorbic Acid Supplements and Kidney Stone Incidence among Men: A Prospective Study. JAMA Internal Medicine, 173, 1-2.
[26] Newberry, S.J. (2012) What Is the Evidence That Vitamin C Supplements Lower Blood Pressure? American Journal of Clinical Nutrition, 95, 997-998. http://dx.doi.org/10.3945/ajcn.112.037663
[27] Staff (2012) Vitamin C: Stress Buster. Psychology Today, 25 April 2003.
http://www.psychologytoday.com/articles/200304/vitamin-c-stress-buster
[28] Polidori, M.C., Mecocci, P. and Frei, B. (2001) Plasma Vitamin C Levels Are Decreased and Correlated with Brain Damage in Patients with Intracranial Hemorrhage or Head Trauma. Stroke, 32, 898-902.
http://dx.doi.org/10.1161/01.STR.32.4.898
[29] Polidori, M.C., Praticó, D., Ingegni, T., Mariani, E., Spazzafumo, L. and Sindaco, P.D. (2005) Effects of Vitamin C and Aspirin in Ischemic Stroke-Related Lipid Peroxidation: Results of the AVASAS (Aspirin versus Ascorbic Acid plus Aspirin in Stroke) Study. BioFactors, 24, 265-274.
http://dx.doi.org/10.1002/biof.5520240131
[30] Zweifler, R.M. (2003) Management of Acute Stroke. Southern Medical Journal, 96, 380-385.
http://dx.doi.org/10.1097/01.SMJ.0000063467.75456.7A

  
comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.